ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CELZ vs JNJ // DIVIDEND YIELD & FCF PAYOUT SAFETY

Creative Medical Technology Holdings Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: CELZ 0 — JNJ 9
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CELZ VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CELZ JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 63.40% 67.90% -4.50 JNJ /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 25.50% -60.50 JNJ /roic <GO>
EV/EBITDA & P/E Valuation — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield — 2.97% — TIE /fcf-yield <GO>
Operating Margin -60.00% 34.70% -94.70 JNJ /operating-margins <GO>
Net Profit Margin -60.00% 28.50% -88.50 JNJ /net-margins <GO>
Revenue Growth (YoY) -45.50% 6.00% -51.50 JNJ /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 5.59 -5.39 JNJ /balance-sheet <GO>
Piotroski F-Score Quality 3/9 8/9 -5.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 36.2 62.1 -25.90 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $5.2M $662.49B -$662.49B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CELZ REV JNJ REV CELZ GROSS % JNJ GROSS % CELZ FCF JNJ FCF
FY 2025 $6.0K $94.19B 63.4% 67.9% -$5.9M $19.70B
FY 2024 $11.0K $88.82B 60.0% 69.1% -$5.3M $19.84B
FY 2023 $9.0K $85.16B — — -$8.0M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CELZ // BETA —
JNJ // BETA 1.08